Mycoplasmal Contamination And Its Impact On The Biopharma Industry

A Q&A With Daniel Lundin, Founder, President, and CEO of Bionique Testing Laboratories, Inc.

Daniel Lundin has over 35 years of experience in cell biology. Since 1990, he has served as president of Bionique Testing Laboratories, an independent contract biotechnology firm specializing in the testing of cell cultures, biologicals, vaccines, and media/sera for mycoplasmal contamination. From 1984 through 1990, he was director of technical services for Bionique Laboratories (the predecessor to Bionique Testing Laboratories).

Prior to joining Bionique, Lundin was laboratory supervisor at W. Alton Jones Cell Science Center, where he participated in the coordination of the cell and tissue culture courses. Outside of the company, Lundin engages in economic development and strategic planning activities directed towards developing and attracting science and technology firms within the Adirondack Park in upstate New York.

In this Q&A, Lundin shares his insights on mycoplasma and its role in the biotechnology and pharmaceutical industries.